Table 1 |
||
|
Baseline group statistics of FRDA patients and healthy controls |
||
|
Parameter |
FRDA (n = 16) |
controls (n = 16) |
|
|
||
|
Age [yr] |
43.8 ± 9.3 (28-59) |
43.1 ± 8.7 (28-60) |
|
Gender (male/female) |
10/6 |
10/6 |
|
Height [m] |
1.72 ± 0.1 (1.59-1.83) |
1.73 ± 0,1 (1.57-1.89) |
|
Weight [kg] |
73.9 ± 9.9 (58-95) |
74.8 ± 9 (56-94) |
|
BSA [m2] |
1.89 ± 0,2 (1.61-2.20) |
1.9 ± 0.2 (1.61-2.16) |
|
GAA shorter allel * |
402 ± 127 (220-560) |
-- |
|
GAA larger allel * |
798.5 ± 250.6 (250-1110) |
-- |
|
GAA product both alleles * |
394492.9 ± 245596.8 (62500-954600) |
-- |
|
Onset of the disease [yr] |
17.2 ± 5.9 (7-30) |
-- |
|
Disease duration [yr] |
26.7 ± 8.7 (8-42) |
-- |
|
SARA |
26.5 ± 7 (9.5-36) |
-- |
|
|
||
|
Values are given as mean ± SD; range (min-max) in brackets; Abbreviations: BSA - body surface area, yr - years, SARA - scale for the assessment and rating of ataxia. *Exact GAA allel length was available for n = 14 |
||
|
Stüwe et al. BMC Neurology 2011 11:145 doi:10.1186/1471-2377-11-145 |
||
